Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | ACACA | Q13085 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8633236 | 0.83 | LTA4H (0.34) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL918878 | 0.82 | NOS1 (0.37) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL918877 | 0.82 | NOS1 (0.37) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL569252 | 0.77 | NOS1 (0.39) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL3294154 | 0.77 | NOS1 (0.42) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL2265477 | 0.77 | SLC7A5 (0.44) | SLC7A5KMT2AGRIK1 | |
| SCHEMBL2265481 | 0.77 | SLC7A5 (0.44) | SLC7A5KMT2AGRIK1 | |
| SCHEMBL27394362 | 0.76 | DGAT1 (0.38) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL375959 | 0.76 | LTA4H (0.36) | LTA4HNOS1NOS3NOS2SLC7A5 | |
| SCHEMBL2611908 | 0.76 | LTA4H (0.36) | LTA4HNOS1NOS3NOS2SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268318-B2 | Polyalkylene oxides having hindered ester-based biodegradable linkers | ENZON PHARMACEUTICALS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | ENZON PHARMACEUTICALS, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-2063709-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | Enzon Pharmaceuticals, Inc. (US) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008034122-A2 | HINDERED ESTER-BASED BIODEGRADABLE LINKERS FOR OLIGONUCLEOTIDE DELIVERY | ENZON PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090232833-A1 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS | CES2, PLOD3, FASN | LTA4H 484/4885NOS1 1169/4885NOS3 736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.